ArticleBlood cell therapy2025
ROLE OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/ REFRACTORY HODGKIN'S LYMPHOMA: RETROSPECTIVE DATA FROM A TERTIARY CARE CENTRE IN INDIA.
Article in Blood cell therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hodgkin Lymphoma is a highly curable malignancy, and relapsed/refractory Hodgkin lymphoma (RRHL) is treated with salvage chemotherapy, followed by autologous stem cell transplant (ASCT). This single-center, retrospective study included patients with RRHL who underwent ASCT. The study included 62 patients with a median age at diagnosis of 22.5 years and a median age at transplant of 24.5 years. Advanced disease at presentation was observed in 64% of the patients. At relapse, 33.3%, 36.6%, and 30% had stage 2, 3, and 4 disease, respectively. Multiple salvage regimens were administered as per the practices at our institution. Among the patients, 63% had complete remission prior to transplant, and 74% underwent ASCT after first-line salvage. Different conditioning regimens were chosen according to institutional practice. Febrile neutropenia was observed in 93.5% of the patients. The treatment-related mortality rate was 4.8% (n=3). The median follow-up duration was 30 months. Median relapse-free survival (RFS) and overall survival (OS) were not reached, and the 3-year RFS and OS rates were 67.1% and 78%, respectively. Factors that adversely influenced OS and RFS were the type of last salvage used and the number of salvage lines prior to transplantation. An advanced stage at the diagnosis was associated with inferior OS but not with RFS. Patients with the refractory disease had inferior RFS and OS rates, of 25.2% and 56.6%, compared with patients with chemoresponsive disease, who had RFS and OS rates of 77% and 84.7%, respectively. ASCT in RRHL showed promising survival, with over two-thirds of the patients surviving without relapse after 3 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.